Pharmacokinetics of Regional Therapy: Isolated Limb Infusion and Other Low Flow Techniques for Extremity Melanoma

Surgical Oncology Clinics of North America

Volumn 17, Issue 4, 2008, Pages 795-804

  Kam, Peter C A ^a,b   Thompson, John F ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BUTATHIONE SULFOXIME; CYTOTOXIC AGENT; FOTEMUSTINE; GLUTATHIONE; HISTAMINE; INTERLEUKIN 2; MELPHALAN; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACIDOSIS; ADD ON THERAPY; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RECURRENCE; CANCER THERAPY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYDROLYSIS; DRUG INFUSION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG TISSUE LEVEL; DRUG TOXICITY; DRUG UPTAKE; GENE THERAPY; GENE VECTOR; HUMAN; HYPOTHERMIA; HYPOXIA; IN VITRO STUDY; INCIDENCE; ISOLATED LIMB INFUSION; LIMB; LIMB TOXICITY; LOW FLOW TECHNIQUE; MELANOMA; MICRODIALYSIS; NONHUMAN; PROGNOSIS; QUALITY OF LIFE; REVIEW; SYSTEMIC CIRCULATION; TECHNIQUE; TEMPERATURE; TOURNIQUET; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 49649095820     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2008.04.003     Document Type: Review

References (42)

1. Lens M.B., and Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150 (2004) 179-185
2. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 19 (2001) 3622-3634
3. Creech Jr. O., Krementz E.T., Ryan R.F., et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148 (1958) 616-632
4. Thompson J.F., Lai D.T., Ingvar C., et al. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 4 Suppl 1 (1994) 45-50
5. Thompson J.F., Hunt J.A., Shannon K.F., et al. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 132 (1997) 903-907
6. Karakousis C.P., Kanter P.M., Lopez R., et al. Modes of regional chemotherapy. J Surg Res 26 (1979) 134-141
7. Bland K.I., Kimura A.K., Brenner D.E., et al. A phase II study of the efficacy of diamminedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques. Ann Surg 209 (1989) 73-80
8. Karakousis C.P., Kanter P.M., Park H.C., et al. Tourniquet infusion versus hyperthermic perfusion. Cancer 49 (1982) 850-858
9. Thompson J.F., Waugh R.C., Saw R.P.M., et al. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Regional Cancer Treatment 7 (1994) 188-192
10. Thompson J.F., and Kam P.C. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 88 (2004) 1-3
11. Brady M.S., Brown K., Patel A., et al. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 13 (2006) 1123-1129
12. Thompson J.F., Kam P.C., Waugh R.C., et al. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 14 (1998) 238-247
13. Lindner P., Doubrovsky A., Kam P.C., et al. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 9 (2002) 127-136
14. Vrouenraets B.C., Hart G.A., Eggermont A.M., et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 188 (1999) 522-530
15. Goldenberg G.J., Lee M., Lam H.Y., et al. Evidence for carrier-mediated transport of melphalan by L5178Y lymphoblasts in vitro. Cancer Res 37 (1977) 755-760
16. Parsons P.G., Carter F.B., Morrison L., et al. Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res 41 (1981) 1525-1534
17. Redwood W.R., and Colvin M. Transport of melphalan by sensitive and resistant L1210 cells. Cancer Res 40 (1980) 1144-1149
18. Wu Z.Y., Smithers B.M., Parsons P.G., et al. The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft. Br J Cancer 75 (1997) 1160-1166
19. Chang S.Y., Alberts D.S., Farquhar D., et al. Hydrolysis and protein binding of melphalan. J Pharm Sci 67 (1978) 682-684
20. Roberts M.S., Wu Z.Y., Siebert G.A., et al. Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat. Melanoma Res 11 (2001) 611-618
21. Wu Z.Y., Smithers B.M., Anderson C., et al. Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment?. Melanoma Res 10 (2000) 47-54
22. Roberts M.S., Wu Z.Y., Siebert G.A., et al. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res 11 (2001) 423-431
23. Thompson J.F., Ramzan I., Kam P.C., et al. Pharmacokinetics of melphalan during isolated limb infusion for melanoma. Regional Cancer Treatment 9 (1996) 13-16
24. Thompson J.F., Siebert G.A., Anissimov Y.G., et al. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer 85 (2001) 157-165
25. Omlor G., Gross G., Ecker K.W., et al. Optimization of isolated hyperthermic limb perfusion. World J Surg 16 (1992) 1117-1119
26. Abdel-Wahab O.I., Grubbs E., Viglianti B.L., et al. The role of hyperthermia in regional alkylating agent chemotherapy. Clin Cancer Res 10 (2004) 5919-5929
27. Cavaliere R., Ciocatto E.C., Giovanella B.C., et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 20 (1967) 1351-1381
28. Grunhagen D.J., de Wilt J.H., van Geel A.N., et al. Isolated limb perfusion for melanoma patients-a review of its indications and the role of tumour necrosis factor-alpha. Eur J Surg Oncol 32 (2006) 371-380
29. Siemann D.W., Chapman M., and Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys 20 (1991) 287-289
30. Skarsgard L.D., Skwarchuk M.W., Vinczan A., et al. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 15 (1995) 219-223
31. Lienard D., Ewalenko P., Delmotte J.J., et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10 (1992) 52-60
32. Cornett W.R., McCall L.M., Petersen R.P., et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 24 (2006) 4196-4201
33. De Wilt J.H., Manusama E.R., Van Etten B., et al. Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions. Br J Cancer 83 (2000) 1176-1182
34. Ueno T., Ko S.H., Grubbs E., et al. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg 188 (2004) 532-537
35. Bonenkamp J.J., Thompson J.F., de Wilt J.H., et al. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol 30 (2004) 1107-1112
36. Brunstein F., Rens J., van Tiel S.T., et al. Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery. Br J Cancer 95 (2006) 1663-1669
37. Green J.A., Vistica D.T., Young R.C., et al. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 44 (1984) 5427-5431
38. Grubbs E.G., Ueno T., Abdel-Wahab O., et al. Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery 136 (2004) 210-218
39. De Roos W.K., De Wilt J.H., Van Der Kaaden M.E., et al. Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas. Ann Surg 232 (2000) 814-821
40. de Wilt J.H., Bout A., Eggermont A.M., et al. Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats. Hum Gene Ther 12 (2001) 489-502
41. Hannay J., Davis J.J., Yu D., et al. Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma. Gene Ther 14 (2007) 671-681
42. Lindner P., Thompson J.F., De Wilt J.H., et al. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol 30 (2004) 433-439